Levodopa/carbidopa/entacapone versus levodopa/dopa-decarboxyiase inhibitor for the treatment of Parkinson's disease: systematic review, meta-analysis, and economic evaluation

Zhan-Miao Yi,1–3 Ting-Ting Qiu,1,4 Yuan Zhang,5 Na Liu,6 Suo-Di Zhai1,3 1Department of Pharmacy, Peking University Third Hospital, 2Department of Pharmacy Administration and Clinical Pharmacy, Peking University School of Pharmaceutical Science, 3Institute for Drug Evaluation, Peking Universit...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	Yi ZM, Qiu TT, Zhang Y, Liu N, Zhai SD
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	Dove Medical Press 2018-04-01
Sarja:	Therapeutics and Clinical Risk Management
Aiheet:	levodopa/carbidopa/entacapone levodopa/dopa-decarboxylase inhibitor Parkinson’s disease efficacy safety cost-effectiveness
Linkit:	https://www.dovepress.com/levodopacarbidopaentacapone-versus-levodopadopa-decarboxyiase-inhibito-peer-reviewed-article-TCRM
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!